Oncolytic peptides kill cancer through multiple immunobiological mechanisms: direct membrane disruption, immunogenic cell death, tumor microenvironment remodeling, and immune cell activation.
4 kill mechanismsOncolytic peptides attack cancer from four angles simultaneously — making it nearly impossible for tumors to develop escape strategies
What the researchers found
Oncolytic peptides: multi-mechanism anticancer action including membrane disruption, immunogenic cell death, TME remodeling, and immune activation — resistant to typical cancer escape strategies.
Why it matters
Understanding how oncolytic peptides engage both direct killing and immune activation enables rational combination therapy design.
How the study worked
Review of immunobiological mechanisms of oncolytic peptide anticancer action.
What this study cannot tell us
Most evidence preclinical. Clinical translation of most oncolytic peptides early-stage.
How to read the evidence
Comprehensive mechanistic review.
When this study was published
Published in 2025.
The bigger picture
Oncolytic peptides combine the best of direct cytotoxics and immunotherapy in single molecules — the ideal cancer treatment paradigm.
Questions still open
- Which oncolytic peptide is closest to clinical approval?
- Would combining oncolytic peptides with checkpoint inhibitors be synergistic?
- Can oncolytic peptides overcome immune-cold tumors?
Common questions
How do oncolytic peptides fight cancer?
Why are multiple mechanisms important?
Read the original research
Immunobiological mechanisms of action of oncolytic peptides.
Journal for immunotherapy of cancer, 14(2)
Citation
Kepp, Oliver; Deng, Xiaolian; Xue, Enfu; Sveinbjørnsson, Baldur; Rekdal, Øystein; Galluzzi, Lorenzo; Kroemer, Guido. (2026). Immunobiological mechanisms of action of oncolytic peptides.. Journal for immunotherapy of cancer, 14(2). https://doi.org/10.1136/jitc-2025-013337